Year Founded
2013
Ownership
Public
Employees
~100
Stage
Phase 3
Modalities
Small molecule

Tricida General Information

Phase 3 VALOR-CKD trial of veverimer did not meet its primary endpoint for treating metabolic acidosis in CKD patients

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

veverimer
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Tricida's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Tricida Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Tricida's complete valuation and funding history, request access »